Aflibercept

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Proliferative Diabetic Retinopathy

Conditions

Proliferative Diabetic Retinopathy

Trial Timeline

Aug 1, 2016 → May 1, 2019

NCT ID

NCT02863354

About Aflibercept

Aflibercept is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Proliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02863354. Target conditions include Proliferative Diabetic Retinopathy.

What happened to similar drugs?

3 of 10 similar drugs in Proliferative Diabetic Retinopathy were approved

Approved (3) Terminated (2) Active (5)

🔄Brolucizumab 6 mgNovartisPhase 3

✅LucentisNovartisApproved

✅RanibizumabNovartisApproved

❌Octreotide, 30 mg i.m. LAR formulationNovartisPhase 3

✅Macugen ® (pegaptanib sodium)PfizerApproved

🔄Intravitreal aflibercept injection [IAI] + ShamRegeneron PharmaceuticalsPhase 3

🔄Ruxolitinib + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01714115	Pre-clinical	Completed	—	—	Retinal Hemangioma
NCT04101721	Phase 3	Completed	Oct 30, 2019	Aug 18, 2022	Retinopathy of Prematurity
NCT03396861	Phase 1	Terminated	Feb 22, 2019	Jan 2, 2020	Irvine-Gass Syndrome
NCT03085784	Phase 2	UNKNOWN	Jul 5, 2017	Oct 1, 2021	Radiation Retinopathy
NCT02863354	Phase 2	Completed	Aug 1, 2016	May 1, 2019	Proliferative Diabetic Retinopathy
NCT02559180	Approved	Completed	Oct 1, 2015	Dec 1, 2020	Diabetic Retinopathy
NCT02503540	Approved	Completed	Aug 18, 2015	Feb 6, 2018	Retinal Vein Occlusion
NCT02299336	Approved	Completed	Nov 24, 2014	Jan 9, 2017	Diabetic Macular Edema
NCT02204683	Phase 1	Completed	Sep 5, 2014	Dec 14, 2016	Neovascular Macular Degeneration
NCT01857544	Approved	UNKNOWN	Jun 1, 2013	Mar 1, 2016	Retinal Vein Occlusion
NCT01722656	Approved	Completed	Nov 1, 2012	Sep 1, 2015	Submacular Vascularized Pigment Epithelial Detachments
NCT01670162	Approved	UNKNOWN	Aug 1, 2012	Jan 1, 2016	Age Related Macular Degeneration
NCT01617148	Approved	Completed	Jun 1, 2012	Dec 1, 2015	Exudative Macular Degeneration
NCT01495208	Approved	Withdrawn	Dec 1, 2011	Oct 1, 2012	Fibrovascular Pigment Epithelial Detachment

Competing Products

20 competing products in Proliferative Diabetic Retinopathy

See all competitors

Product	Company	Stage	Hype Score
LY2784544	Eli Lilly	Phase 1	29
LY2784544	Eli Lilly	Phase 1	29
Navitoclax + Ruxolitinib + Celecoxib	AbbVie	Phase 1	33
Epcoritamab	AbbVie	Phase 1	36
Brolucizumab 6 mg	Novartis	Phase 3	40
CANAKINUMAB (ILARIS®)	Novartis	Phase 1	21
Lucentis	Novartis	Approved	43
Ranibizumab	Novartis	Approved	39
Octreotide, 30 mg i.m. LAR formulation	Novartis	Phase 3	32
Ranibizumab 0.5 mg	Novartis	Phase 2	35
AUY922	Novartis	Phase 2	27
Lucentis	Roche	Pre-clinical	22
Macugen (pegaptanib) + Macugen (Pegaptanib)	Pfizer	Pre-clinical	26
Macugen ® (pegaptanib sodium)	Pfizer	Approved	39
Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine	Swedish Orphan Biovitrum	Phase 2	42
Fedratinib Pill	Bristol Myers Squibb	Phase 2	39
VAC85135 + Ipilimumab	Bristol Myers Squibb	Phase 1	29
Fedratinib Pill	Bristol Myers Squibb	Phase 1	21
Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg	Bristol Myers Squibb	Phase 1	21
2-mg Intravitreous Aflibercept Injection	Regeneron Pharmaceuticals	Phase 2/3	38